Eidos Therapeutics, Inc. (EIDX) relating to its proposed acquisition by BridgeBio Pharma, Inc. Under the terms of the agreement, Eidos’ shareholders will receive 1.85 shares of BridgeBio common stock or $73.26 in cash per share.
Eidos Therapeutics, Inc. (EIDX) relating to its proposed acquisition by BridgeBio Pharma, Inc. Under the terms of the agreement, Eidos’ shareholders will receive 1.85 shares of BridgeBio common stock or $73.26 in cash per share.